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ABSTRACT
Purpose. Controversy exists regarding the optimal nega-
tive margin width for ductal carcinoma in situ (DCIS)
treated with breast-conserving surgery and whole-breast
irradiation.
Methods. A multidisciplinary consensus panel used a
meta-analysis of margin width and ipsilateral breast tumor
recurrence (IBTR) from a systematic review of 20 studies
including 7,883 patients and other published literature as
the evidence base for consensus.
Results. Negative margins halve the risk of IBTR com-
pared with positive margins defined as ink on DCIS. A
2-mm margin minimizes the risk of IBTR compared with
smaller negative margins. More widely clear margins do
not significantly decrease IBTR compared with 2-mm
margins. Negative margins narrower than 2 mm alone are
not an indication for mastectomy, and factors known to
affect rates of IBTR should be considered in determining
the need for re-excision.
Conclusion. Use of a 2-mm margin as the standard for an
adequate margin in DCIS treated with whole-breast irra-
diation is associated with lower rates of IBTR and has the
potential to decrease re-excision rates, improve cosmetic
outcomes, and decrease health care costs. Clinical judg-
ment should be used in determining the need for further
surgery in patients with negative margins narrower than 2
mm.
Breast-conserving therapy (BCT), defined as surgical
excision of the primary tumor with a margin of surrounding
normal tissue followed by whole-breast irradiation
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(WBRT), results in long-term cause-specific survival rates
of greater than 95% for women with ductal carcinoma
in situ (DCIS), as demonstrated in both randomized trials1
and observational studies.2,3 Although the addition of
WBRT to surgical excision does not improve survival, it
substantially reduces rates of ipsilateral breast tumor
recurrence (IBTR), even among patients with smaller, non-
high-grade DCISs.1,4 Microscopically clear margins,
defined as no ink on tumor, were required in three5–7 of the
four early randomized trials of WBRT for DCIS, but not in
the fourth.8 These studies provide no information on
whether more widely clear margins than no ink on tumor
would reduce rates of IBTR in patients receiving BCT.
Retrospective single-institution studies have suggested
that a negative margin width of 1 cm or more may elimi-
nate the reduction in IBTR seen with WBRT,9 leading
some to conclude that larger margins are also beneficial in
patients undergoing WBRT. Despite the widespread use of
BCT for DCIS, there is still no consensus on what con-
stitutes an optimal negative margin width.10 As a
consequence, approximately one in three women attempt-
ing BCT for DCIS undergo re-excision.11 Re-excisions
have the potential for added discomfort, surgical compli-
cations, compromise in cosmetic outcome, additional stress
for patients and families, and increased health care costs
and have been associated with conversion to bilateral
mastectomy.12
Since BCT was established, the landscape of DCIS
management has evolved, with advances in imaging and
pathologic evaluation and the availability of adjuvant
endocrine therapy, resulting in a decline in IBTR rates.13 In
view of these changes and the lack of consensus on what
represents adequate negative margins in DCIS, the Society
of Surgical Oncology (SSO), American Society for Radi-
ation Oncology (ASTRO), and American Society of
Clinical Oncology (ASCO) convened a multidisciplinary
margins panel (MP) to evaluate IBTR in relation to margin
width. The primary question addressed was: ‘‘What margin
width minimizes the risk of IBTR in patients with DCIS
receiving breast-conserving surgery?’’ The guideline
developed from this consensus panel is intended to assist
treating physicians and patients in the clinical decision-
making process based on the best available evidence. The
key findings of the guideline are summarized in Table 1.
METHODS
Guideline Development
The guideline development process was funded by a
Susan G. Komen grant. Committee members were chosen
by their respective organizations based on interest and
expertise in DCIS management (Table 2). Processes rec-
ommended in the Institute of Medicine report ‘‘Clinical
Practice Guidelines We Can Trust’’14 that were followed as
part of the guideline development process included:
development of a systematic review– or study-level meta-
analysis based on questions to be addressed by the MP to
serve as the primary evidence base, with additional topic-
specific literature reviews conducted by participants for
questions not addressed in the meta-analysis; provision for
each recommendation of a rating of the strength of the
evidence and strength of the recommendation; ascertain-
ment of the level of agreement of panel members with each
recommendation by vote, and revision of recommendations
to achieve greater than 90% consensus; and declaration by
MP candidates of potential conflicts of interest before
convening, and obtainment of written disclosures at the
consensus meeting. (The co-chairs deemed no MP mem-
bers had conflicts that could influence the process or
development of specific recommendations.)
The MP convened in November 2015; the resulting
manuscript was approved by all panel members and
externally reviewed, and feedback was incorporated. The
final manuscript was approved by the SSO Executive
Council, ASTRO Board of Directors, and ASCO Board of
Directors, and endorsed by the Board of Directors of the
American Society of Breast Surgeons. Patient-related
materials will be available on the Susan G. Komen Web
site.15
Meta-Analysis
The methodology for the systematic review/meta-anal-
ysis has been published elsewhere.16 Briefly, using
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) and Institute of Medicine
guidelines, EMBASE, MEDLINE, PREMEDLINE, and
evidence-based medicine databases were searched in
October 2014 for eligible studies. A summary providing
details of the methodology and statistical approaches is
provided in the Appendix (online only). Analysis was
performed using two different statistical approaches. In the
frequentist approach, multiple margin cut points within
studies, if reported, were condensed into a single cut point,
whereas the Bayesian approach allowed for the use of
multiple cut points.17 All reported odds ratio (ORs) were
adjusted for study-specific median follow-up time (to
account for the inherent increased risk of IBTR with longer
follow-up) and are reported relative to positive (or posi-
tive/close) margins or to a minimal negative margin (no ink
on tumor or margin[ 1 mm).16
Inclusion and Exclusion Criteria Studies that included a
minimum of 50 patients with DCIS treated with local
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TABLE 1 Summary of Clinical Practice Guideline Recommendations
Clinical question Recommendation Strength of
recommendation
Level of evidence Strength
of
evidence
Consensus on
recommendation
Are positive margins associated
with an increased risk of
IBTR? Can the use of WBRT
mitigate this increased risk?
A positive margin, defined as
ink on DCIS, is associated
with a significant increase in
IBTR; this increased risk is
not nullified by the use of
WBRT
Strong Meta-analysis (patient level)
of RCTs (not primary end
point); meta-analysis
(study level) of
observational studies;
individual RCT
Strong 100%
What margin width minimizes
the risk of IBTR in patients
undergoing WBRT?
Margins C 2 mm are associated
with a reduced risk of IBTR
relative to narrower negative
margin widths in patients
receiving WBRT
Moderate Meta-analysis (study level)
of observational studies
Moderate 100%
The routine practice of
obtaining negative margin
widths[ 2 mm is not
supported by the evidence
Strong Strong
Is treatment with excision alone
and widely clear margins
equivalent to treatment with
excision and WBRT?
Treatment with excision alone,
regardless of margin width,
is associated with
substantially higher rates of
IBTR than treatment with
excision and WBRT (even in
predefined low-risk patients)
Strong Meta-analysis (patient level)
of RCTs; individual RCT
Strong 100%
What is the optimal margin
width for patients treated
with excision alone?
The optimal margin width for
treatment with excision alone
is unknown, but should be at
least 2 mm. Some evidence
suggests lower rates of IBTR
with margin widths wider
than 2 mm
Moderate Meta-analysis (study level)
of observational studies;
prospective single-arm
studies; retrospective
studies
Moderate 100%
What are the effects of
endocrine therapy on IBTR?
Is the benefit of endocrine
therapy associated with
negative margin width?
Rates of IBTR are reduced with
endocrine therapy, but there
is no evidence of an
association between
endocrine therapy and
negative margin width
Weak RCTs Weak 100%
Should margin widths[ 2 mm
be considered in the presence
of unfavorable factors such
as comedo necrosis, high
grade, large size of DCIS,
young patient age, negative
ER status, or high-risk
multigene panel scores?
Multiple factors have been
shown to be associated with
the risk of IBTR in patients
treated with and without
WBRT, but there are no data
addressing whether margin
widths should be influenced
by these factors
Weak Expert opinion Weak 100%
Should margin width be taken
into consideration when
determining WBRT delivery
technique?
Choice of WBRT delivery
technique, fractionation, and
boost dose should not be
dependent on negative
margin width; there is
insufficient evidence to
address optimal margin
widths for APBI
Weak Retrospective studies; expert
opinion
Weak 100%
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excision and reported IBTR in relation to microscopic
margin widths with a minimum median follow-up of 4
years were eligible.16
Study Quality and Literature Limitations All publications
in the meta-analysis (except two) were retrospective and
provided observational data at the study level. The
characteristics of these studies have been reported
elsewhere.16
Results The meta-analysis included 20 studies, 7,883
patients with DCIS with known margin status, and 865
IBTRs.16 The median proportion of patients undergoing
WBRT was 100% (interquartile range [IQR], 53.3% to
100.0%), and the median proportion receiving endocrine
therapy was 20.8% (IQR, 0.0% to 31.4%). The median
follow-up was 78.3 months, and the median incidence of
IBTR was 8.3% (IQR, 5.0% to 11.9%). Because of
heterogeneity in classification and reporting of margins
data, both a frequentist analysis and a Bayesian network
meta-analysis were conducted with sensitivity analyses.
Characteristics of patients included in the studies are
summarized in Table 3.16
GUIDELINE RECOMMENDATIONS
Positive Margins
A positive margin, defined as ink on DCIS, is associated
with a significant increase in IBTR. This increased risk is
not nullified by the use of WBRT. There is no debate that
a positive margin, defined as the presence of ink from the
specimen surface on ducts containing DCIS, implies a
potentially incomplete resection and is associated with a
higher rate of IBTR. In the Early Breast Cancer Trialists’
Collaborative Group (EBCTCG) meta-analysis of
randomized DCIS trials,1 patients with positive margins
had a two-fold higher IBTR risk compared with patients
with negative margins despite receiving WBRT (10-year
IBTR rate, 24% v 12 %), and approximately 50% were
invasive recurrences. The relationship between margin
status and WBRT was examined in a subset analysis of the
TABLE 1 continued
Clinical question Recommendation Strength of
recommendation
Level of evidence Strength
of
evidence
Consensus on
recommendation
Should DCIS with
microinvasion be considered
as invasive carcinoma or
DCIS when determining
optimal margin width?
DCIS with microinvasion,
defined as no invasive focus
[ 1 mm in size, should be
considered as DCIS when
considering the optimal
margin width
Weak Expert opinion Weak 100%
APBI, accelerated partial-breast irradiation; DCIS, ductal carcinoma in situ; ER, estrogen receptor; IBTR, ipsilateral breast tumor recurrence;
RCT, randomized controlled trial; WBRT, whole-breast irradiation
TABLE 2 Expert panel members
Panel Member Society Affiliation
Mariana Chavez-MacGregor, MD ASCO University of Texas MD Anderson Cancer Center
Jay R. Harris, MD ASTRO Harvard Medical School
Janet Horton, MD ASTRO Duke University Medical Center
Nehmat Houssami, MBBS, PhD School of Public Health Sydney Medical School, University of Sydney
E. Shelley Hwang, MD, MPH ASBS Duke University Medical Center
Peggy L. Johnson Patient Advocate Advocate in Science, Susan G. Komen
M. Luke Marinovich, PhD School of Public Health Sydney Medical School, University of Sydney
Meena S. Moran, MD (co-chair) ASTRO Yale University
Monica Morrow, MD (co-chair) SSO Memorial Sloan Kettering Cancer Center
Stuart J. Schnitt, MD CAP Beth Israel Deaconess Medical Center and Harvard Medical School
Lawrence Solin, MD ASTRO Albert Einstein Healthcare Network
Irene Wapnir, MD SSO Stanford University
Kimberly J. Van Zee, MS, MD SSO Memorial Sloan Kettering Cancer Center
ASBS, American Society of Breast Surgeons; ASCO, American Society of Clinical Oncology; ASTRO, American Society for Radiation
Oncology; CAP, College of American Pathology; SSO, Society of Surgical Oncology
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National Surgical Adjuvant Breast and Bowel Project
(NSABP) B-17 trial by central pathology review of 573 of
818 participants.18 The annual hazard rate for IBTR after
lumpectomy alone was 8.1 % for those with positive
margins compared with 3.3% for patients with negative
margins, reduced by WBRT to 2.7% and 1.2%,
respectively. Positive margins were significantly
associated with IBTR in a multivariable analysis of the
long-term results of the European Organisation for
Research and Treatment of Cancer (EORTC) 10853
trial.19 In the meta-analysis by Marinovich et al16 using
the Bayesian analytic approach, similar results were
obtained. After adjustment for study-level follow-up,
patients with negative margins were significantly less
likely to experience IBTR than patients with positive
margins (OR, 0.45; 95% credible interval [CrI], 0.30 to
0.62). Similar findings were observed in the frequentist
analysis, which necessitated combining positive and close
margins (OR, 0.53; 95% CI, 0.45 to 0.62; P\ .001). This
result persisted after study-level adjustment for age,
median recruitment year, grade of DCIS, use of WBRT,
and use of endocrine therapy.
Negative Margin Widths
Margins of at least 2 mm are associated with a reduced
risk of IBTR relative to narrower negative margin widths in
patients undergoing WBRT. The routine practice of
obtaining negative margin widths wider than 2 mm is not
supported by the evidence.
To address the question of optimal negative margin
width, the MP considered data on the distribution of DCIS
in the breast. Studies of mastectomy specimens using
whole-organ sectioning and radiologic–pathologic corre-
lation have demonstrated that although most cases of DCIS
are unicentric, the involvement of the segment may be
multifocal, with so-called gaps of uninvolved tissue
between foci of DCIS.20 Given this, a negative margin does
not guarantee the absence of residual DCIS in the breast.
There are also technical limitations to margin assess-
ment that affect the relationship between margin width and
IBTR. For example, margins are artifactually narrower
ex vivo, when specimens become flattened from lack of
surrounding supportive tissue, a phenomenon exaggerated
by compression for specimen radiography. Additionally,
surface ink can track into deeper portions of the specimen,
posing significant challenges in determining true margin
location. Finally, tumor-to-ink distance on any single slide
may not be representative of the entire specimen; an ade-
quate margin on one section may become positive if
additional or deeper sections are examined. Two common
methods for margin evaluation include sectioning perpen-
dicular to ink (to determine tumor-to-ink width) or en-face
examination of shaved margins (where any residual tumor
in the shaved specimen is considered a positive margin).
Although an advantage of the shaved method is greater
surface-area examination, a known disadvantage is the
higher frequency of margins categorized as positive that
are, in comparison, negative by the perpendicular method,
which may in turn result in unnecessary re-excision or even
mastectomy.21 Specimen sampling is also highly variable,
and even total sequential embedding results in only a small
proportion (\ 1%) of the specimen margins being exam-
ined.22 Together, these studies highlight the substantial
variability in margin assessment irrespective of the tech-
nique used.
Despite variability in margin assessment, great emphasis
has been placed on achieving specific negative margin
widths. In the frequentist meta-analysis by Marinovich
et al,16 comparison of specific margin width thresholds (2,
3 or 5, and 10 mm) relative to negative margins defined as
TABLE 3 Summary of study characteristics included in meta-
analysis
Characteristic No. of Studies* Value or Proportion
Across Studies
Median Range
Patient age, years 20 53.7 43.0–62.1
Type of IBTR
DCIS 17 50.0% 0.0%–75.0%
Invasive 17 50.0% 25.0%–100.0%
Unknown 17 0.0% 0.0%–7.1%
Screen detected
Yes 14 85.8% 45.6%–100.0%
No 14 14.2% 0.0%–54.4%
Unknown 14 0.0% 0.0%–2.8%
Grade
I 13 17.5% 1.8%–64.5%
II 13 28.0% 5.5%–45.0%
I–II 16 57.3% 7.3%–92.5%
III 16 28.4% 3.5%–45.6%
Unknown 16 9.2% 0.0%–87.3%
Hormone receptor status
Positive 5 50.4% 23.0%–80.4%
Negative 5 8.7% 2.8%–14.3%
Unknown 5 40.9% 14.8%–69.8%
Median WBRT dose, Gy 11 50.0 42.5–50.0
Radiation boost 19 70.9% 0.0%–100%
Median boost dose, Gy 8 10.0 10.0-10.8
NOTE. Data adapted.16
Abbreviations: DCIS, ductal carcinoma in situ; IBTR, ipsilateral
breast tumor recurrence; WBRT, whole-breast irradiation
*Refers to studies contributing information on the characteristic,
including studies with subsets of patients missing data for the
characteristic
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wider than 0 or 1 mm included 7,883 patients with a
median follow-up of 6.5 years. The ORs for 2 mm (0.51;
95% CI, 0.31 to 0.85; P = .01), 3 or 5 mm (0.42; 95% CI,
0.18 to 0.97; P = .04), and 10 mm (0.60; 95% CI, 0.33 to
1.08; P = .09) showed comparable reductions in the odds of
IBTR compared with wider than 0 or 1 mm, and pairwise
comparisons found no significant differences in the odds of
IBTR between the 2-, 3- or 5-, and 10-mm margin
thresholds (all P[ .40). In this model, the predicted 10-
year IBTR probability for 2-mm negative margins was
10.1% (95% CI, 6.3% to 16.0%) compared with 8.5% for
3- or 5-mm (95% CI, 3.6% to 18.9%) and 11.7% (95% CI,
6.7% to 19.4%) for 10-mm margins. In the Bayesian net-
work meta-analysis (Table 4),16 the ORs of incrementally
wider negative margins relative to the positive margin
category were 0.45 (95% CrI, 0.32 to 0.61) for wider than 0
or 1 mm, 0.32 (95% CrI, 0.21 to 0.48) for 2 mm, 0.30 (95%
CrI, 0.12 to 0.76) for 3 mm, and 0.32 (95% CrI, 0.19 to
0.49) for 10 mm. Adjustments for clinically relevant
covariates, including sensitivity analysis limited to studies
using radiation therapy (RT), did not alter these mean OR
estimates (Table 4). In this analysis, the relative OR of
IBTR between the 10- and 2-mm threshold groups com-
pared with positive margins was 0.99 (95% CrI, 0.61 to
1.64), indicating no statistically meaningful difference.
The choice of the 2-mm threshold rather than wider than
0 (no ink on tumor) or 1 mm was based on evidence of a
statistically significant decrease in IBTR for 2 mm com-
pared with 0 or 1 mm in the frequentist analysis (OR, 0.51;
95% CI, 0.31 to 0.85; P = .01), coupled with weak evi-
dence in the Bayesian model of a reduction in IBTR with
the 2-mm distance compared with smaller distances (rela-
tive OR, 0.72; 95% CrI, 0.47 to 1.08). However, although
the MP felt that there was evidence that the 2-mm margin
optimized local control, clinical judgment must be used in
determining whether patients with smaller negative margin
widths ([0 or 1 mm) require re-excision. Factors felt to be
important to consider include assessment of IBTR risk
TABLE 4 Margin threshold and IBTR: Bayesian network meta-analysis
Analysis Threshold distance for negative margins relative to positive (mm)
Mean OR (95% CrI)*
[0 or 1 2 3 10
Main model, no. of patients 2,230 2,412 289 1,963
All studies 0.45 (0.32 to 0.61) 0.32 (0.21 to 0.48) 0.30 (0.12 to 0.76) 0.32 (0.19 to 0.49)
Sensitivity analysis, no. of patients 1,957 1,851 272 1,079
RT cohorts only 0.45 (0.34 to 0.61) 0.33 (0.23 to 0.47) 0.22 (0.08 to 0.53) 0.37 (0.24 to 0.57)
Sensitivity analysis, no. of patients 1,781 1,524 289 616
Van Zee et al22 excluded 0.43 (0.31 to 0.57) 0.29 (0.19 to 0.45) 0.32 (0.14 to 0.75) 0.27 (0.16 to 0.47)
Sensitivity analysis, no. of patients 2,230 2,412 — 1,963
3 mm excluded 0.47 (0.34 to 0.63) 0.34 (0.23 to 0.49) — 0.36 (0.23 to 0.56)
Sensitivity analysis, no. of patients 2,692 2,555 322 2,160
Adding studies with no summary age data 0.44 (0.30 to 0.63) 0.31 (0.19 to 0.51) 0.32 (0.14 to 0.73) 0.20 (0.11 to 0.35)§
Adjustment for covariates (based on main model)
Age 0.46 (0.33 to 0.63) 0.34 (0.22 to 0.51) 0.33 (0.13 to 0.83) 0.33 (0.20 to 0.51)
Median recruitment year 0.45 (0.31 to 0.62) 0.31 (0.19 to 0.46) 0.29 (0.12 to 0.68) 0.32 (0.20 to 0.49)
Proportion with RT 0.46 (0.33 to 0.63) 0.33 (0.22 to 0.49) 0.29 (0.12 to 0.74) 0.32 (0.20 to 0.50)
Proportion with endocrine therapy> 0.45 (0.29 to 0.70) 0.33 (0.18 to 0.57) 0.29 (0.10 to 0.79) 0.31 (0.17 to 0.57)
Proportion with high-grade DCIS> 0.45 (0.32 to 0.62) 0.33 (0.21 to 0.48) 0.31 (0.12 to 0.74) 0.39 (0.25 to 0.59)
Data adapted.16
Abbreviations: CrI, credible interval; DCIS, ductal carcinoma in situ; IBTR, ipsilateral breast tumor recurrence; OR, odds ratio; RT, radiation
therapy
* Adjusted for follow-up
 Two studies using a 5 mm threshold were included with the 3 mm threshold group
 These studies were ineligible for inclusion in the meta-analysis from Marinovich et al because of lack of summary age data (see eligibility
criteria); hence sensitivity analysis reports estimates if these were included in models
§ 95% CrI for relative odds ratio of 10 v[ 0 or 1 mm did not cross 1 (Methods Meta-Analysis)
> Because of missing covariate information, these analyses were undertaken in a reduced number of studies (19 for endocrine therapy; 16 for
high-grade DCIS)
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(residual calcifications on postexcision mammography,
extent of DCIS in proximity to margin, and which margin
is close [i.e. anterior excised to skin or posterior excised to
pectoral fascia v margins associated with residual breast
tissue]), cosmetic impact of re-excision, and overall life
expectancy. The conclusion that re-excision could be
selectively employed with margins smaller than 2 mm was
influenced by the high long-term rates of local control
reported in the NSABP DCIS trials,7 which required a
margin of no ink on tumor, as well as the study by Van Zee
et al,23 which, after adjusting for multiple covariates, found
no difference in risk between margins of 2 mm or narrower
and more widely clear margins in patients receiving
WBRT.
Treatment with Excision Alone
Treatment with excision alone, regardless of margin
width, is associated with substantially higher rates of IBTR
than treatment with excision and WBRT, even in predefined
low-risk patients. The optimal margin width for treatment
with excision alone is unknown but should be at least 2 mm.
Some evidence suggests lower rates of IBTR with margin
widths wider than 2 mm.
The EBCTCG DCIS meta-analysis showed that the 10-
year IBTR rate for patients treated with excision alone was
higher than that with excision and WBRT, both for those
with negative (26.0% v 12.0%; P \ .001) and positive
margins (48.3% v 24.2%; P\ .001).1 The same propor-
tional benefit for WBRT was seen in women treated with
local excision and those having large sector resections. In
the Radiation Therapy Oncology Group (RTOG) 9804
trial, where patients with small, mammographically
detected low- to intermediate-grade DCIS and margins of 3
mm or wider were randomly assigned to excision alone or
excision plus WBRT, 7-year IBTR rates were 6.7% and
0.9% (P \ .001), respectively.4 The prospective, multi-
institutional Eastern Cooperative Oncology Group (ECOG)
E5194 study of patients with low-risk DCIS treated with
excision alone (negative margin width C 3 mm) reported
12-year rates of IBTR of 14.4% for non–high-grade DCIS
2.5 cm or smaller in size and 24.6% for high-grade DCIS 1
cm or smaller in size. However, IBTR rates did not differ
significantly for margins narrower than 5, 5 to 9, or 10 mm
or wider (P = .85).24 A prospective single-arm study of
patients with mammographically detected DCIS 2.5 cm or
smaller in size reported a 10-year IBTR rate of 15.6%,25
despite requiring margins of 1 cm or wider.4 In contrast,
Van Zee et al23 found in 1,266 patients treated with exci-
sion alone that the 10-year IBTR rate was 16% for margins
wider than 10 mm and increased to 23% for margins
between 2.1 and 10 mm, 27% for margins greater than 0 to
2 mm, and 41% for positive margins. After adjustment for
multiple factors, margin width was a more highly signifi-
cant predictor of IBTR (P\.001). The MP felt that overall,
the heterogeneity of the evidence among these studies did
not allow for a definitive recommendation for margin
widths greater than 2 mm in patients foregoing RT.
Endocrine Therapy
Rates of IBTR are reduced with endocrine therapy, but
there is no evidence of an association between endocrine
therapy and negative margin width.
Tamoxifen reduces the incidence of both IBTR and
contralateral breast cancer, but the absolute benefit is rel-
atively small.7,26 In the NSABP B-24 trial, patients treated
with lumpectomy and WBRT were randomly assigned to
tamoxifen or placebo; 25% of the population had positive
or unknown margins. The 15-year IBTR rate for the pla-
cebo group was 17.4% in those with positive margins
compared with 7.4% for clear margins. Adjuvant tamox-
ifen lowered IBTR rates among those with positive
margins to levels similar to those in the negative-margin
cohort (placebo, 17.4%; tamoxifen, 11.5%); conversely,
there was little impact of tamoxifen in the negative-margin
cohort (IBTR: placebo, 7.4%; tamoxifen, 7.5%).7 Hence,
the MP felt that although tamoxifen decreased IBTR in
patients with positive margins, there was no evidence to
suggest an association between negative margin width and
benefit of endocrine therapy.
Patient and Tumor Features
Multiple factors have been shown to be associated with
the risk of IBTR in patients treated with and without
WBRT, but there are no data addressing whether margin
widths should be influenced by these factors.
Young patient age has consistently been associated with
IBTR, and tumor factors such as histologic pattern, comedo
necrosis, and nuclear grade and size of DCIS also modify
the risk of IBTR.18,27,28 More recently, unfavorable gene
profile scores have also been associated with IBTR.29,30
However, there are no data addressing whether margin
widths should be influenced by these factors, and this
represents an appropriate area for further study.
Radiation Delivery
Choice of WBRT delivery technique, fractionation, and
boost dose should not be dependent on negative margin
width. There is insufficient evidence to address optimal
margin widths for accelerated partial-breast irradiation
(APBI).
A vast majority of patients treated in the five prospective
randomized DCIS trials of excision with or without WBRT
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underwent conventionally fractionated WBRT without a
boost. Only one of the trials allowed the option of
hypofractionated WBRT in addition to standard WBRT,4
and 10% or fewer of the patients in three of the trials
received a boost.6–8 None of the randomized trials varied
RT technique according to margin status, and neither
intensity-modulated RT nor APBI were used. There is no
direct evidence from randomized trials to support the use of
a boost to the primary tumor site for patients with DCIS,
although in patients with invasive breast carcinoma, the
long-term value of a boost in reducing IBTR has been
demonstrated.31
Two ASTRO consensus guidelines have addressed tech-
nical issues in the setting of BCT. Although largely focusing
on invasive breast carcinoma, the ASTRO statement on
hypofractionated WBRT concluded there was insufficient
evidence to recommend for or against hypofractionated
WBRT in the setting of DCIS.32 In the ASTRO statement on
APBI, DCIS was placed in the cautionary group based on the
lack of evidence from randomized trials; however, it was
noted that patients with DCIS have been included in some
retrospective cohort studies.33
Therefore, there is no evidence that margin width, in
isolation, should determine radiation delivery technique,
fractionation of WBRT, or use or dose of a boost. The MP
considered the evidence base insufficient to address opti-
mal margin width in APBI.
DCIS in Presence of Invasive Breast Cancer
DCIS with microinvasion (DCIS-M), defined as no
invasive focus larger than 1 mm in size, should be con-
sidered DCIS when determining optimal margin width.
There are two diagnoses for which there is overlap
between our DCIS margin guideline and the SSO-ASTRO
invasive cancer margin guideline:34 DCIS-M and invasive
carcinoma associated with DCIS (extensive intraductal
component or lesser amounts of scattered DCIS). In DCIS-
M, defined by the American Joint Committee on Cancer as
the extension of cancer cells beyond the basement mem-
brane with no focus more than 0.1 cm in greatest
dimension,35 small retrospective studies have suggested
that rates of IBTR are similar to those seen with pure
DCIS.36,37 In the absence of specific data to address margin
width in DCIS-M, the MP, based on expert opinion, felt
that DCIS-M should be considered DCIS when determin-
ing the optimal margin width, given that the majority of the
lesion is composed of DCIS and that systemic therapy
utilization for DCIS-M more closely reflects the treatment
pattern for DCIS than for invasive carcinoma.
In contrast, when considering margin width for an
invasive cancer with a DCIS component, regardless of
extent, the MP felt that the invasive cancer guideline34 was
applicable, primarily because the natural history and
treatment of these lesions are more similar to those of
invasive cancer than DCIS, even when the close margin
contains DCIS. In particular, a vast majority of patients
with invasive cancer receive systemic therapy, which
remains less common for pure DCIS. The invasive cancer
guideline34 does note that an extensive intraductal com-
ponent is a marker for a potential heavy burden of residual
DCIS and that postexcision mammography, presence of
multiple close margins, and young patient age can be used
to select patients who will benefit from re-excision. These
statements echo the discussion of the MP regarding the use
of re-excision in pure DCIS with margins narrower than 2
mm discussed previously, and thus, we believe the guide-
lines are compatible.
DISCUSSION
There are limitations to this guideline. It applies to
patients with DCIS and DCIS-M treated with WBRT. The
findings should not be extrapolated to patients with DCIS
treated with APBI or those with invasive carcinoma, for
whom a separate guideline has been developed.34 Although
studies including patients treated with and without WBRT
were included in the meta-analysis, a meta-analysis of
studies of treatment with excision alone was not conducted.
Additionally, all of the studies included in the meta-anal-
ysis were retrospective. However, in the absence of any
planned prospective randomized trials addressing the
question of margin width and local recurrence, these
studies represent the best available evidence for clinical
decision making.
ACKNOWLEDGEMENT Supported by a grant from Susan G.
Komen; by a National Breast Cancer Foundation (NBCF; NBCF
Australia) Breast Cancer Research Leadership Fellowship (N.H.); and
by Cancer Institute New South Wales Fellowship (M.L.M.).
DISCLOSURE The authors have no conflicts of interest to
disclose.
APPENDIX
The methods for the meta-analysis are described in full by
Marinovich et al16 and are summarized briefly here.
Study Eligibility Criteria
Eligible studies enrolled 50 women or more with ductal
carcinoma in situ receiving breast-conserving surgery,
allowed calculation of the crude local recurrence (LR) rate
by microscopic margin status, defined negative margins by
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a numeric threshold, reported mean or median age, and
presented mean or median follow-up of 48 months or longer.
Literature Search and Data Extraction
MEDLINE, PREMEDLINE, EMBASE, and all evi-
dence-based medicine reviews were searched in October
2014. One investigator screened citations, with a sample
independently screened by a second. Two investigators
independently extracted data; disagreements were arbi-
trated by a third investigator.
Statistical Analysis
Frequentist models (random effects logistic
metaregression) Margins were dichotomized into
positive/close versus negative margin status using one
distance threshold per study ([ 0 or 1, 2, 3 or 5, and 10
mm). The association between LR and margin status and
distance was modeled using random effects logistic
metaregression. Odds ratios (ORs) are presented for
negative relative to positive/close margins, and threshold
distances relative to wider than 0 or 1 mm.
Bayesian models (network meta-analysis) Network meta-
analysis using mixed treatment comparisons used data
from single or multiple thresholds within studies (when
presented) to compare directly (within study) and indirectly
(between studies) the probability of LR between margin
categories (positive, [ 0 or 1, 2, 3, and 10 mm). ORs
compare negative versus positive margins, and distance
categories relative to positive margins.
Assessment of covariates All models were adjusted for
study-level follow-up time. Other covariates were assessed
for their effect on model estimates (age, median year of
recruitment, proportion of patients who received endocrine
therapy, proportion of patients with high-grade ductal
carcinoma in situ, and proportion of patients undergoing
whole-breast irradiation).
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